指南与共识神经MR

阿尔茨海默病治疗中 MRI 检出 ARIA 的 AI 工具:专家意见与临床整合建议

Artificial Intelligence-Based Detection of ARIA on MRI During Alzheimer Disease Therapy: Expert Opinion on Responsible Clinical Integration.
指南 / 共识 · AJR Am J Roentgenol · 2026-09-16

多学科神经放射与阿尔茨海默病临床专家评估了 AI 辅助检出 MRI 上淀粉样相关影像异常(ARIA)的证据。专家组认为在放射科医师参与的框架下,AI 辅助 ARIA 检测有助于提升患者安全。专家支持在医师监督、持续质量保证和前瞻性临床性能监测下有条件实施。

要点

  • AI 辅助 ARIA 检测应在放射科医师监督下作为临床决策支持使用。
  • 不同商用工具在监管状态、技术能力与验证证据方面差异明显。
  • ARIA 检测结果可能影响治疗继续、剂量调整与安全评估。

核心结论

  • 专家组认为 AI 辅助 ARIA 检测在放射科医师参与的框架内可能提升患者安全。
  • 专家组支持在放射科医师监督、持续质量保证和前瞻性性能监测下有条件实施。

研究设计与样本

  • 多学科专家组由神经放射科医师与阿尔茨海默病临床医师组成,基于证据形成专家意见。
  • 来源为 AJR Am J Roentgenol 发布的专家意见,未报告具体样本量或中心数。

临床应用与阅片要点

  • ARIA 影像表现可能影响抗淀粉样治疗的继续、剂量调整和患者安全评估。
  • 抗淀粉样治疗扩大应用后监测 MRI 量增加、阅片者间差异及漏检风险值得关注。
  • 有条件实施时需保持医师复核、持续质量保证并前瞻性监测工具临床性能。

局限性

  • 专家组指出需要进一步研究评估检出能力改善对临床结局的影响。
  • 不同商用工具在监管状态、技术能力和验证证据方面存在实质差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Amyloid-targeted monoclonal antibody therapies have introduced a new era in the treatment of early Alzheimer disease. However, their use has increased the importance of detecting and monitoring amyloid-related imaging abnormalities (ARIA) on MRI, as such findings may influence treatment continuation, dose modification, and patient safety assessment. As anti-amyloid therapies expand into routine practice, increasing surveillance MRI volumes, interreader variability, and the potential for missed subtle abnormalities have generated interest in artificial intelligence (AI)-based clinical decision support tools. A multidisciplinary panel of neuroradiologists and Alzheimer disease clinicians examined the extent of evidence supporting clinical implementation of AI-assisted ARIA detection tools, these tools' safe integration into practice, and remaining evidence gaps. The panel concluded that AI-assisted ARIA detection is likely to enhance patient safety when used as clinical decision support within a radiologist-in-the-loop framework. Panelists also noted substantial variation among commercially available tools in regulatory status, technical capabilities, and validation evidence. Moreover, they emphasized the need for further studies to assess the impact of improved detection on clinical outcomes. Overall, the panel supported conditional implementation with radiologist oversight, ongoing quality assurance, and prospective monitoring of clinical performance.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Petrella, Barkhof, Benzinger, et al. Artificial Intelligence-Based Detection of ARIA on MRI During Alzheimer Disease Therapy: Expert Opinion on Responsible Clinical Integration. AJR Am J Roentgenol. 2026. PMID: 42747213. doi:10.2214/AJR.26.35514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。